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Introduction
Interferon beta (IFN-beta) is a first-choice thera-
peutic strategy for patients with relapsing–remitting
(RR) multiple sclerosis (MS) [1] and those with sec-
ondary progressive (SP) MS experiencing continuing
relapse activity [2, 3]. Neutralizing antibodies
(NABs) against IFN-beta may occur in variable
percentages of patients [2, 4–8]. The clinical signif-
icance of NABs has been a matter of controversy and
has been extensively investigated ever since the ini-
tial descriptions in MS patients [9–23]. Monitoring
blood levels for IFN-beta-induced compounds and
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resistant protein A (MxA) and
dsRNA-dependent protein kinase
(PKR) were measured before (pre-
dose) and 24 hours after (post-
dose) IFN-beta administration in
49 patients with multiple sclerosis
(MS) with (n = 25) and without
(n = 24) NABs.
The results indicated that pre-
dose levels of MxA-mRNA and
PKR-mRNA were highly variable
[coefficient of variation (CV) >
100%] among patients. A lower
inter-individual variability was
observed for pre-dose levels of
Beta2-MG and neopterin (CVs of
29% and 44%, respectively).
Significantly lower pre- and
post-dose blood levels of IFN
induced markers, except for post-
dose PKR-mRNA (p = 0.09), were
seen in NAB+ compared with
NAB– patients and between pa-
tients with high (> 200 t1/10) and
low (£ 200 t1/10) NAB titers. A
significant inverse correlation be-
tween NAB titer and pre-dose
levels of the above IFN-induced
markers was found. In summary,
our findings confirm that NABs
affect absolute concentrations of
IFN-beta induced markers and
suggest that such an effect occurs
in a titer-dependent manner.
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interesting approach to studying the in vivo biolog-
ical effects of NABs.
Serum concentrations of IFN-induced compounds
have been examined already to some extent, in pa-
tients with RRMS undergoing IFN-beta therapy.
Decreases in serum levels of neopterin, beta2-mi-
croglobulin (Beta2-MG) and in peripheral blood
mononuclear cell (PBMC) concentrations of mixo-
virus-resistant protein A (MxA)-mRNA were found
in RRMS patients who developed NABs [24–31].
However, the findings were contradictory [28]. Fur-
ther questions still remain as to whether lack of
efficacy of IFN-beta in NAB+ patients is related to
these antibodies in a titer-dependent manner. In-
deed, while some studies described an association
between NAB titer and loss of IFN-beta biological
response[24, 27–29, 31], others failed to demonstrate
such an association [25, 30].
In order to gain new insights into these issues, the
pharmacodynamic profile of IFN-beta in patients with
MS, both with and without NABs, was first defined by
measuring neopterin, Beta2-MG and MxA-mRNA
concentrations in blood immediately before and
24 hours after IFN-beta injection. In addition, pre-
and post-dose intracellular levels of the IFN-induced
dsRNA-dependent protein kinase (PKR)-mRNA were
also determined.
The changes in PBMC PKR-mRNA have been so
far only marginally studied in patients with MS [32].
To address the role of NAB titers in affecting the
pharmacodynamics of IFN-beta patients with NABs
were finally classified in two different groups based on
NAB titers.
Materials and methods
j Patients and study design
49 patients with clinically definite MS according to Poser criteria
[33], who were undergoing therapy with recombinant (r) IFN-be-
ta1b (Betaferon, Schering, Berlin, Germany) given at 8 · 106 IU
subcutaneously (SC) every other day were included consecutively
in this cross-sectional study. All patients were required to sign an
informed consent form prior to inclusion. Local Ethics Committees
and/or Institutional Review Boards approved the study.
In Table 1 the demographics and clinics of patients at the time
of sample collection are summarized. Patients with NABs had been
undergoing therapy for 2.8 ± 1.9 years, while NAB– patients had
been taking IFN-beta for 4.1 ± 1.7 years (p = 0.08).
Samples for each individual were collected according to the
following scheme: (i) pre-dose, that is immediately before an rIFN-
beta1b injection, corresponding to 48 hours (up to 72 hours in a
few cases) after the previous rIFN-beta1b injection; (ii) post-dose,
that is 24 hours after an rIFN-beta1b injection (18 hours in a very
few cases). Pre-dose samples served for NAB measurements,
whereas pre- and post-dose samples were collected for measure-
ment of blood concentrations of Beta2-MG, neopterin, MxA and
PKR.
The timing of sample collection was based upon both ethical
and biological considerations representing a trade-off between
feasibility and optimal data acquisition. First, only two sample
collections (i.e. pre- and post-dose) were considered to be accept-
able by a local ethics committee. Second, previous studies showed
that changes in type I-IFN-induced compounds (i.e. Beta2-MG,
neopterin and MxA protein) are still sustained 24 hours after IFN-
beta injection in patients with RRMS [26, 28, 31, 34].
In the light of the above-mentioned considerations, samples
were collected at 24-hours post-dose in the present study.
j Biological evaluations
Venous peripheral blood from each patient was drawn into tubes
containing ethylenediaminetetraacetic acid and into anticoagulant-
free tubes. PBMCs were separated using Ficoll-Hypaque gradient
sedimentation; 5 · 106 PBMCs were collected, pelleted and frozen at
–80C until required. Serum samples, obtained after centrifugation,
were stored at –80C until used.
j Detection of IFN-beta NAB
Antibody titers were determined by neutralization against 10 IU of
rIFN-beta1b as previously described [6]. Sera were routinely inac-
tivated at 56C for 30 minutes before titration. Then 60ll of twofold
serial dilutions (starting from 1:10) of sample or control sera were
incubated at 37C with 60 ll containing 20 IU/ml of rIFN-beta.
After 1 hour, 100 ll of individual mixtures were added to duplicate
monolayers of human lung carcinoma (A549) cells in 96-well mi-
crotiter plates. After 18–24 hours of culture and extensive washing,
the cells were challenged with the encephalomyocarditis virus and
incubated at 37C for 24 hours. Controls included a titration of the
IFN preparations used in the respective assays and of a reference
standard antibody to IFN-beta (National Institutes of Health,
Bethesda, MD; code GO38-501-572). Any antiviral activity and its
neutralization were assessed on the basis of the virus-induced cy-
tophatic effect (CPE), and to quantify this, the cells were stained
with crystal violet in 20% ethanol. The dye taken up by the cells was
eluted with 33% acetic acid and its absorbance measured in a
microdensitometer at 540 nm (OD540). The extent of virus-induced
Table 1 Demographics and clinics of patients (NABs, neutralizing antibodies; MS, multiple sclerosis; RR, relapsing–remitting; SP, secondary progressive; EDSS,
expanded disability status scale)
Patients without NABs (n = 24) Patients with NABs (n = 25)
Age (years)* 41.0 ± 11.3 45.2 ± 12.9
Gender (females/males) 19/5 19/6
MS duration (years)* 13.8 ± 8.7 10.7 ± 3.8
Disease course RR (10); SP (14) RR (9); SP (16)
EDSS* 5.3 ± 1.6 4.5 ± 1.6
* mean ± SD
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CPE, its inhibition by IFN-beta, and the reversal of this by NABs
were shown by the amount of dye eluted from each well. Titers were
calculated using Kawade¢s method and expressed logarithmically as
t1/10, namely the dilution of serum reducing 10 laboratory units
(LU) per ml of IFN to 1 LU/ml [35].
Serum samples were routinely assayed for, and all were found to
be free from, endogenous or residual IFN activity.
The neutralizing activity of the titred sera (‡ 80 t1/10 that cor-
responds to (‡ 1.9 Log) was characterized as being due specifically
to the presence of IFN antibodies as previously described [36].
Patients were assigned to one of three groups according to their
NAB status: NAB-negative (NAB–), NAB low positive (£ 200 t1/10,
which corresponds to £ 2.3 Log; LP-NAB+) and NAB high positive
(> 200 t1/10, which corresponded to >2.3 Log; HP-NAB+).
j Detection of neopterin and Beta2-MG
Serum concentration of neopterin (DRG Instruments GmbH,
Marburg, Germany) and Beta2-MG (S.P.A. Italiana Laboratori
Bouty, Milan, Italy) were immunoassayed following the manufac-
turer¢s instructions using sera stored at –80 C until tested. Serum
samples were tested in duplicate.
j Taqman quantitative RT-PCR for MxA- and PKR-mRNA
MxA and PKR genes transcripts in PBMCs from MS patients were
quantified by a real time 5¢ exonuclease reverse transcript-poly-
merase chain reaction (RT-PCR Taqman) assay using the ABI 7700
sequence detector (Applied Biosystems, Monza, Italy). Briefly, total
cell RNA and DNA were concomitantly extracted from 5 X106
PBMCs using Trizol reagent (Gibco BRL, NY, USA) following the
manufacturer¢s instructions. The RNA was dissolved in 50 ll of
RNAse-free water and the quantitation of MxA- or PKR-mRNA was
performed in a Taqman assay after generation of cDNA. The
following primers and probe for MxA (forward primer, 5¢-CTGCC
TGGCAGAAAACTTACC-3¢ reverse primer, 5¢-CTCTGTTATTCTC
TGGTGAGTCTCCTT-3¢ probe, 5¢CATCACACATATCTGTAAA
TCTCTGCCCCTGTTAGA-3¢) or for PKR (forward primer, 5¢-
TGCTACTACGTGTGAGTCCCAAA-3¢ reverse primer, 5¢- TGATG
TATCTGCTGAGAAGTCACCT-3¢ probe, 5¢-CAACTCTTTAGTGA
CCAGCACACTCGCTTCT-3¢) were added to the universal PCR
master mix (Applied Biosystems, Foster City, CA, USA) at 300 and
100 nM, respectively, in a final volume of 50 ll. The standards were
obtained by cloning the 525 bp MxA fragment or 394 bp PKR
fragment into the pCRII plasmid using a TOPO TA cloning kit (In
Vitrogen Corporation, San Diego, CA, USA). The DNA from the
cloned plasmids was subsequently transcribed using SP6/T7 RNA
polymerase under the conditions recommended by the supplier
(Promega Corporation, Madison, WI, USA). A linear distribution
(r = 0.99) was obtained between 101 and 108 copies of MxA- or
PKR-RNA.
PBMC-MxA and PKR transcripts were normalized to DNA
values and expressed as the number of copies of MxA- or PKR-
mRNAs/ng DNA. DNA levels were measured by using a spectro-
photometer at 260 nm.
j Statistical analysis
Descriptive statistics were provided for the entire population to
report patient demographics/clinics and blood concentrations of
neopterin, Beta2-MG, and MxA- and PKR-mRNA.
The coefficient of variation (CV) was used to measure inter-
patient variability in blood concentrations of biological products.
The CV is the ratio of the standard deviation (SD) of the mean of
each variable to the mean, expressed as a percentage [CV = (100)
(SD/mean)]. Relative increases in levels of neopterin, Beta2-MG,
and MxA-and PKR-mRNA from pre- to post-dose were given as the
post- to pre-dose levels ratio. Absolute increases above baseline
were given by the differences between post- and pre-dose values.
Differences between patient groups in terms of blood concentra-
tions and relative or absolute increases in surrogate biological
markers for IFN action were analyzed using the Kruskal–Wallis
test. Follow-up Mann–Witney U tests were undertaken when dif-
ferences were found. Pearson¢s r coefficient was calculated to assess
the correlation between levels of Beta2-MG, neopterin, and Log
MxA/PKR-mRNA with Log NAB titers.
Statistical analysis was performed by SPSS v.11 for Windows.
A p-value of £ 0.05 was considered significant throughout the
statistical analyses.
Results
j Inter-patient variability in pre- and post-dose lev-
els of neopterin, Beta2-MG, and MxA- and
PKR-mRNAs
Individual levels of neopterin, Beta2-MG, and MxA-
and PKR-mRNAs at pre- and post-dose are shown in
Figure 1. Pre-dose CVs were 44%, 29% for neopterin
and Beta2-MG, and >100% for MxA- and PKR-mRNAs;
post-dose CVs were 45%, 28% for neopterin and Beta2-
MG and >100% for MxA- and PKR-mRNAs. This
finding demonstrates a marked interpatient variability
in the steady-state and IFN-induced levels of markers
in patients with MS undergoing IFN-beta treatment.
j Influence of NAB on the expression of IFN-induced
markers
Absolute pre- and post-dose levels of each IFN induced
marker in NAB+ and NAB– patients, expressed as mean
(± SD) and median, are shown in Table 2. NAB+ pa-
tients had significantly lower concentrations of each
marker at each time point except for Beta2-MG blood
post-dose concentrations (p = 0.09). When patients
were grouped together as NAB–, LP-NAB+ and
HP-NAB+ (see Table 2), the highest (p < 0.02) mean
values of neopterin, Beta2-MG, and MxA- and PKR-
mRNAs were observed in NAB– patients compared
with either LP-NAB+ or HP-NAB+ patients. The
exceptions were the values of PKR-mRNA at post-dose,
which were found to be lower, although not signifi-
cantly (p = 0.09) in HP-NAB+ patients versus
LP-NAB+ patients. The lowest values were found in HP-
NAB+ patients compared with each remaining group.
Significant inverse correlations between the Log
titer of NABs and the pre-dose expression of neop-
terin (r = –0.54; p < 0.05), Beta2-MG (r = –0.34;
p < 0.05), Log MxA-mRNA (r = –0.49; p < 0.05), and
Log PKR-mRNA (r = –0.35; p < 0.05) were recorded.
Upon examining IFN beta-induced modifications
of the values of each compound, it was found that no
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differences in increases relative to baseline were
present in NAB–, LP-NAB+ and HP-NAB+ patients
(Figure 2). The latter suggests that NAB probably do
not abolish completely the capability of IFN beta to
exert its biological activity.
Discussion
Several approaches have been used to establish
whether the development of NABs affects the
pharmacodynamics of IFN-beta in patients with MS.
Our results confirm that IFN-beta NABs reduce
pre- and post-dose blood concentrations of several
IFN-induced markers. There were, however, some
further findings, which we consider, deserve some
attention.
The present study indicates, for the first time to
our knowledge that the measurement of PKR-mRNA
is worth taking into account when studying the
pharmacodynamic profile of IFN-beta in MS patients.
Questions remain as to whether PKR protein mea-
surements provide a clinically useful marker for
monitoring and predicting the effectiveness of IFN-
beta in MS patients, as this study was not powered
and designed for this purpose.
High inter-patient variability was observed in
neopterin and Beta2-MG pre- and post-dose serum
levels, as well as in PBMC MxA and PKR pre- and
post-dose transcripts. This finding is not new and is
most likely due to heterogeneity in the immunology of
patients with MS. Indeed, Chieux and co-authors [37]
reported that, in contrast to moderate differences in
MxA expression in healthy individuals, clinically
Table 2 Influence of NABs on expression of interferon-induced markers (NABs, neutralizing antibodies; LP, low positive; HP, high positive; Beta2-MG,
beta2-microglobulin; MxA, myxovirus-resistant protein A; PKR, dsRNA-dependent protein kinase)
NAB– (n = 24) All NAB+ (n = 25) LP-NAB+ (n = 13) HP-NAB+ (n = 12)
Neopterin (nmol/l) Pre-dose 9.6 ± 3.3 (9.5) 6.2 ± 2.8 (5.6) 7.6 ± 2.8 (7.3) 4.7 ± 2.4 (4.2)
Post-dose 10.7 ± 4.1 (10.8) 6.9 ± 2.7 (6.8) 8.2 ± 2.4 (8.6) 5.5 ± 2.7 (4.5)
Beta2-MG (lg/ml) Pre-dose 2.5 ± 0.6 (2.5) 2.1 ± 0.5 (1.9) 2.3 ± 0.7 (2.4) 1.9 ± 0.5 (1.9)
Post-dose 2.6 ± 0.7 (2.6) 2.2 ± 0.5 (2.2) 2.6 ± 0.6 (2.5) 2.0 ± 0.5 (1.9)
MxA-mRNA (copies/ng DNA) Pre-dose 20433.7 ± 27671.3 (11980.6) 6016.5 ± 11076.9 (1744.5) 6712.2 ± 6831.9 (4789.1) 1340.4 ± 1442.0 (636.3)
Post-dose 37486.4 ± 48604.3 (16498.6) 9699.4 ± 14488.1 (2955.1) 15217.3 ± 17184.1 (5998.6) 1815.1 ± 1879.8 (914.9)
PKR-mRNA (copies/ng DNA) Pre-dose 5629.0 ± 5832.3 (4224.7) 2077.3 ± 2481.5 (1190.5) 1978.9 ± 1761.0 (1385.6) 1415.0 ± 1543.8 (1095.6)
Post-dose 11600.3 ± 19439.9 (4985.0) 3324.7 ± 4414.9 (778.1) 3777.8 ± 5003.0 (1729.0) 2620.1 ± 3951.2 (587.3)
Values are expressed in mean ± SD (median)
Fig. 1 Change of neopterin (panel
A), Beta2-MG (panel B), Log MxA-
mRNA (panel C) and Log PKR-mRNA
(panel D) expression levels after
rIFN-beta1b injection in the entire
patients group. (Beta2-MG, beta2-
microglobulin; MxA, mixovirus-
resistant protein A; PKR, dsRNA-
dependent protein kinase; rIFN,
recombinant interferon)
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stable patients with RRMS have high inter-individual
variance in MxA expression. This observation has
been extended here and our results support the idea
that each MS patient might possess a specific and
individual capacity to respond to IFN-beta. Several
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Fig. 2 Post/pre-dose ratios of neopterin (panel A) and Beta2-MG (panel B), peripheral blood mononuclear cells MxA-mRNA (panel C), PKR-mRNA (panel D) in NAB–
(< 10 t1/10), LP-NAB+ (( 200 t1/10) and HP-NAB+ (£ 200 t1/10) patients. (Beta2-MG, beta2-microglobulin; MxA, myxovirus-resistant protein A; PKR, dsRNA-dependent
protein kinase; NAB, neutralizing antibody; LP, low positive; HP, high positive) Box and whiskers plots are used to present data. In these graphs, boxes represent
interquartile ranges; horizontal bars stand for median value; vertical bars extend to the smallest and the largest observations within 1, 5 interquartile range from the
extremes of the box. Outliers are displayed as individual points
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ability, including the immunological (e.g. change in
Th1/Th2 ratio or cross-talk from other cytokine-
activated pathways) and genetic characteristics of
patients [38–41].
Apart from these speculations, the reasons for the
high level of inter-individual variability remain un-
clear at present.
While differences were found between patients
with and without NABs, in pre and post-dose con-
centrations of neopterin and Beta2-MG as well as
MxA and PKR specific transcripts (Table 2), and in
absolute increases over the baseline of the same
markers (data not shown), no differences were seen in
the relative post-injection increase in any of the
examined compounds (Figure 2). The latter has not
been previously investigated and was an intriguing
finding. Several considerations can be formulated in
order to explain our finding. First one could speculate
that as soon as IFN-beta is administered it reaches its
target cells being free to exert its action. Later on,
when the molecule reaches the bloodstream, it can be
exposed to the neutralization effect of circulating
NABs.
Second, little is known about the reaction of anti-
IFN antibody neutralization in terms of molar
concentrations. The latter would deserve further
investigations in order to understand the neutraliza-
tion capability of NABs. At present, we may only
speculate that following IFN-beta injection, NABs do
not neutralize all IFN molecules and those left can
still bind to the receptor, thus allowing some effec-
tor expression. Third, binding between IFN and
NAB is reversible and anti-IFN-beta NABs with
different affinity and specificity have been demon-
strated in vivo [42–45].
It is tempting to speculate that the above factors
may influence the efficiency of the NAB neutralization
reaction. Recently we obtained evidence that the de-
gree of IFN-beta-induced expression of markers may
strictly depend on their pre-dose levels (Scagnolari C,
et al., unpublished). This suggests that the ratio post/
pre-dose, rather than the absolute increases, may be
more representative of the effector mechanism elic-
ited by IFN-beta treatment.
Whatever the explanation is, further studies are
warranted in order to better understand these pre-
liminary findings. A more extensive pharmacody-
namic profile would possibly provide further insights.
It seems also possible that at least in some instances
the level of induction of IFN- beta-induced mark-
ers decreases during IFN-beta treatment due to a
‘‘tachyphylaxis-like’’ phenomenon [28]. These con-
siderations have to be taken into account to fully
understand the capability of NAB to neutralize the
activity of IFN-beta.
A third possible source of variability, may derive
from circadian variations because in this study, drug
injection and sample collection after 24 hours did not
always occur at the same time of the day.
Even considering all these limitations, our data
provide new insights in the capability of NABs to
completely impede IFN action in vivo.
Our data also indicate a correlation between NAB
titers and the expression of IFN-action markers.
More specifically, we observed that HP-NAB+ pa-
tients (e.g. > 200t1/10) were associated with a marked
inhibition of the in vivo biological response com-
pared with NAB– or LP-NAB+ patients. This is in
accordance with previous studies, which showed a
significant decrease in Beta2-MG, neopterin and
MxA protein in patients with persistently high levels
of NABs [24, 27–29, 31] but contradicts others who
found that IFN-beta bioavailability was completely
abolished, irrespective of NAB titers [25].
This discrepancy can be explained by considering
that other factors beside NABs could affect IFN-beta
bioactivity in patients with MS. These include
abnormal IFN signalling [46], decreased expression of
the IFN type I receptor on the cell surface [47], release
of free IFN-alpha/beta type I receptors into the cir-
culation [48, 49] and the presence of IFN type I
inhibitory proteins [48, 50]. Recently it has been
shown that two members of the suppressor of cyto-
kine signalling (SOCS) protein family, SOCS-1 and
SOCS-3, also inhibit IFN-induced expression of the
antiviral proteins 2¢5¢-OAS and MxA [51].
In conclusion our data demonstrate that the
development of NABs in patients with MS during
therapy leads to a decrease in absolute pre- and
post-dose levels and changes in surrogate markers for
IFN. However, the data also indicate that surrogate
markers for IFN increase significantly on IFN-beta
administration, even in the presence of NABs. Hence,
serum NABs seem to be unable to abolish entirely the
effects of IFN-beta administration. Whether this effect
of NABs is fully NAB titer-dependent is still debatable
and warrants further investigation in larger cohorts of
patients and at shorter intervals.
The main aim of this study was to address in detail
the pharmacodynamics of IFN-beta in the presence of
serum circulating NAB, and not to address the general
issue of NAB impact from a clinical point of view. In
order to reach definite conclusions on this issue, fur-
ther studies combining clinical and biological investi-
gations in the same individuals are certainly warranted.
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